chemotherapy

The study provides a more accurate tool for stratifying patients with HER2-positive breast cancer

MiRNA can be used as a biomarker to predict disease recurrence and mortality in breast cancer patients

Researchers at the University of Galway have found that biomarkers known as microRNAs can help predict which breast cancer patients are likely to face disease recurrence and death. Scientists led by Dr. Matthew Davey, Professor Michael Kerin and Dr. Nicola Miller of the University’s College of Medicine, Nursing and Health Sciences conducted a multicentre study …

MiRNA can be used as a biomarker to predict disease recurrence and mortality in breast cancer patients Read More »

The study provides a more accurate tool for stratifying patients with HER2-positive breast cancer

The study provides a more accurate tool for stratifying patients with HER2-positive breast cancer

Patients with a type of breast cancer called HER2-positive have a lower chance of survival if their initial treatment fails to completely eradicate the tumor and they have high levels of tumor-infiltrating immune cells called lymphocytes in the residual disease. Dr Federica Miglietta said on the 13thThursday European Breast Cancer Conference that normally tumor-infiltrating lymphocytes …

The study provides a more accurate tool for stratifying patients with HER2-positive breast cancer Read More »

Liquid biopsy can save colon cancer patients from chemotherapy

Liquid biopsy can save colon cancer patients from chemotherapy

CHICAGO – Early colon cancer patients who have been found circulating tumor DNA in their blood may need more aggressive treatment, but people who have a negative liquid biopsy seem safe to avoid chemotherapy – without an increased risk of recurrence, the researchers suggested. . About 28% of patients diagnosed with stage II colon cancer …

Liquid biopsy can save colon cancer patients from chemotherapy Read More »

ctDNA has been shown to be effective as a treatment decision tool for adjuvant chemotherapy in colon cancer

ctDNA has been shown to be effective as a treatment decision tool for adjuvant chemotherapy in colon cancer

Controlled approaches using circulating tumor DNA can reduce the number of patients receiving adjuvant chemotherapy without the risk of reducing recurrence-free survival in some patients with stage II colon cancer. Controlled approaches using circulating tumor DNA (ctDNA) may, according to the DYNAMIC Phase 2 study, reduce the number of patients receiving adjuvant chemotherapy without the …

ctDNA has been shown to be effective as a treatment decision tool for adjuvant chemotherapy in colon cancer Read More »